Loading ...
Sorry, an error occurred while loading the content.

16254FW: NATAP: VX-950 Study Results So Far

Expand Messages
  • alleypat@comcast.net
    Nov 1, 2006
      NATAP http://natap.org/

      These reports were presented at EASL in Vienna Spring 2006:

      VX-950 HCV Protease Inhibitor Resistance Profile - (05/02/06)

      Initial Results of a 14-Day Study of the Hepatitis C Virus Protease Inhibitor VX-950, In Combination with Peginterferon-alfa-2a - (05/02/06)

      Subsequent to EASL at DDW, the 28-day study in which VX-950 was stopped but patients continued with Pegasys+RBV was reported:
      VX-950 HCV Protease Inhibitor + Pegasys/RBV: 28 days study results in treatment-naive - (05/24/06)
      NATAP nataphcv mailing list -- nataphcv@...

      [Non-text portions of this message have been removed]